Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP)

Toxicon

Volumn 55, Issue 2-3, 2010, Pages 662-665

  Torii, Yasushi ^a,b   Takahashi, Motohide ^c   Ishida, Setsuji ^c   Goto, Yoshitaka ^a   Nakahira, Shinji ^a   Harakawa, Tetsuhiro ^a   Kaji, Ryuji ^d   Kozaki, Shunji ^b   Ginnaga, Akihiro ^a  

^a Kaketsuken   (Japan)

^b Osaka Prefecture University   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Botulinum toxin; CMAP; ELISA; Mouse neutralization test

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BOTULINUM TOXIN F; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOUSE; MUSCLE ACTION POTENTIAL; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SERODIAGNOSIS;

ACTION POTENTIALS; ANIMALS; ANTITOXINS; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICE; MICE, INBRED ICR; MUSCLE, SKELETAL;

EID: 72749095728     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.09.004     Document Type: Article

References (16)

1. Borodic G., Johnson E., Goodnough M., and Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46 1 (1996) 26-29
2. Byrne M.P., Smith T.J., Montgomery V.A., and Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 66 10 (1998) 4817-4822
3. Casale R., and Tugnoli V. Botulinum toxin for pain. Drugs R. D. 9 1 (2008) 11-27
4. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov. Disord. 19 Suppl. 8 (2004) S92-S100
5. Eleopra R., Tugnoli V., Rossetto O., De Grandis D., and Montecucco C. Different time course of recovery after poisoning with botulinum neurotoxin serotypes A and E in human. Neurosci. Lett. 256 3 (1998) 135-138
6. Eleopra R., Tugnoli V., Quatrale R., Rossetto O., and Montecucco C. Different types of botulinum toxin in humans. Mov. Disord. 19 Suppl. 8 (2004) S53-S59
7. Hatheway C.H., Snyder J.D., Seals J.E., Edell T.A., and Lewis Jr. G.E. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J. Infect. Dis. 150 3 (1984) 407-412
8. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatr. 75 7 (2004) 951-957
9. Jones R.G.A., Corbel M.J., and Sesardic D. A review of WHO international standards for botulinum antitoxins. Biologicals 34 3 (2006) 223-226
10. Kessler K.R., and Benecke R. The EDB test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov. Disord. 12 1 (1997) 95-99
11. Mezaki T., Kaji R., Kohara N., Fujii H., Katayama M., Shimizu T., Kimura J., and Brin M.F. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 45 3 Pt 1 (1995) 506-508
12. Sakaguchi G., Ohishi I., and Kozaki S. Purification and oral toxicities of Clostridium botulinum progenitor toxins. In: Lewis G.E. (Ed). Biomedical Aspects of Botulism (1981), Academic Press, New York pp. 21-34
13. Sesardic D., Jones R.G., Leung T., Alsop T., and Tierney R. Detection of antibodies against botulinum toxins. Mov. Disord. 19 Suppl. 8 (2004) S85-S91
14. Torii Y., Tokumaru Y., Kawaguchi S., Izumi N., Maruyama S., Mukamoto M., Kozaki S., and Takahashi M. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 20 19-20 (2002) 2556-2561
15. Torii, Y., Goto, Y., Takahashi, M., Ishida, S., Harakawa, T., Sakamoto, T., Kaji, R., Kozaki, S., Ginnaga, A. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins. Toxicon, in press.
16. Truong D.D., and Jost W.H. Botulinum toxin: clinical use. Parkinsonism Relat. Disord. 12 6 (2006) 331-355